A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Dihomo-gamma linolenic acid (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors DS Biopharma
  • Most Recent Events

    • 25 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 07 Jan 2016 Primary endpoint has been met. (IGA (Investigators Global Assessment)), according to a DS Biopharma media release.
    • 07 Jan 2016 According to a DS Biopharma media release, the Company intends to present the full results at an appropriate dermatology conference later in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top